Braden, MR. Towards a biophysical understanding of hallucinogen action Ph. D. Thesis, Purdue University, West Lafayette, IN, 1 Jan 2007. 8.4 MB. #S,S-trans
Ray, TS. Psychedelics and the human receptorome PLOS ONE, 2 Feb 2010, 5 (2), e9019. 791 kB. https://doi.org/10.1371/journal.pone.0009019
Nichols, DE; Frescas, SP; Marona-Lewicka, D; Kurrasch-Orbaugh, DM. Lysergamides of isomeric 2,4-dimethylazetidines map the binding orientation of the diethylamide moiety in the potent hallucinogenic agent N,N-diethyllysergamide (LSD) J. Med. Chem., 1 Sep 2002, 45 (19), 4344–4349. 268 kB. https://doi.org/10.1021/jm020153s #2c MS,NMR
Brandt, SD; Kavanagh, PV; Westphal, F; Elliott, SP; Wallach, J; Colestock, T; Burrow, TE; Chapman, SJ; Stratford, A; Nichols, DE; Halberstadt, AL. Return of the lysergamides. Part II: Analytical and behavioural characterization of N6-allyl-6-norlysergic acid diethylamide (AL-LAD) and (2′S,4′S)-lysergic acid 2,4-dimethylazetidide (LSZ) Drug Test. Anal., 1 Jan 2017, 9 (1), 38-50. 1.6 MB. https://doi.org/10.1002/dta.1985 LC,MS,NMR,IR,UV
Chapman, SJ; Burns, D; Burrow, TE. 1H and 13C NMR spectra of (2′S,4′S)-lysergic acid 2,4-dimethylazetidide (LSZ) BLOTTER, 15 Jul 2016, 2 (2). 24.9 MB. https://doi.org/10.16889/isomerdesign-4 NMR
Nichols, DE. Structure-activity relationships of serotonin 5-HT2A agonists WIREs Membr. Transp. Signal, 1 Sep 2012, 1 (5), 559-579. 573 kB. https://doi.org/10.1002/wmts.42 #24
Wacker, D; Wang, S; McCorvy, JD; Betz, RM; Venkatakrishnan, AJ; Levit, A; Lansu, K; Schools, ZL; Che, T; Nichols, DE; Shoichet, BK; Dror, RO; Roth, BL. Crystal Structure of an LSD-Bound Human Serotonin Receptor Cell, 26 Jan 2017, 168 (3), 377–389.e12. 5.4 MB. https://doi.org/10.1016/j.cell.2016.12.033
Brandt, SD; Kavanagh, PV; Twamley, B; Westphal, F; Elliott, SP; Wallach, J; Stratford, A; Klein, LM; McCorvy, JD; Nichols, DE; Halberstadt, AL. Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775) Drug Test. Anal., 1 Feb 2018, 10 (2), 310-322. 1.2 MB. https://doi.org/10.1002/dta.2222 GC,LC,MS,NMR,IR,UV,other
EMCDDA. New drugs in Europe, 2013, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 Jul 2014. 311 kB.
Morris, H. Underground LSD palace Hamilton’s Pharmacopeia, 19 Oct 2012. S1 E04, 19:20. Vice 128.0 MB.
Nichols, DE. Chemistry and structure–activity relationships of psychedelics In Behavioral Neurobiology of Psychedelic Drugs; Halberstadt, AL; Vollenweider, FX; Nichols, DE, Eds., Springer, 1 Jan 2017; pp 1-43. 2.6 MB. https://doi.org/10.1007/7854_2017_475 #29
Halberstadt, AL; Geyer, MA. Effect of hallucinogens on unconditioned behavior In Behavioral Neurobiology of Psychedelic Drugs; Halberstadt, AL; Vollenweider, FX; Nichols, DE, Eds., Springer, 1 Jan 2017; pp 159-199. 879 kB. https://doi.org/10.1007/7854_2016_466
Nichols, DE. DARK classics in chemical neuroscience: Lysergic acid diethylamide (LSD) ACS Chem. Neurosci., 17 Oct 2018, 9 (10), 2331–2343. 1.1 MB. https://doi.org/10.1021/acschemneuro.8b00043
Wagmann, L; Richter, LHJ; Kehl, T; Wack, F; Bergstrand, MP; Brandt, SD; Stratford, A; Maurer, HH; Meyer, MR. In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures Anal. Bioanal. Chem., 1 Jul 2019, 411 (19), 4751-4763. 3.8 MB. https://doi.org/10.1007/s00216-018-1558-9 #43 MS
McCorvy, JD. Mapping the binding site of the 5-HT2A receptor using mutagenesis and ligand libraries: Insights into the molecular actions of psychedelics Ph. D. Thesis, Purdue University, 1 Jan 2012. 3.9 MB. #S,S Azetidide
Halberstadt, AL; Chatha, M; Klein, AK; Wallach, J; Brandt, SD. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species Neuropharmacology, 1 May 2020, 167, 107933. 2.4 MB. https://doi.org/10.1016/j.neuropharm.2019.107933 #SS-LSZ
Sexton, JD; Nichols, CD; Hendricks, PS. Population survey data informing the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics Front. Psychiatry, 11 Feb 2020, 10 (896). 529 kB. https://doi.org/10.3389/fpsyt.2019.00896 #LSZ
Brandt, SD; Kavanagh, PV; Westphal, F; Stratford, A; Elliott, SP; Dowling, G; Halberstadt, AL. Analytical profile of N-ethyl-N-cyclopropyl lysergamide (ECPLA), an isomer of lysergic acid 2,4-dimethylazetidide (LSZ) Drug Test. Anal., 16 Aug 2020, 12 (1), 1514-1521. 7.7 MB. https://doi.org/10.1002/dta.2911 #LSZ MS,NMR,IR,UV
Cumming, P; Scheidegger, M; Dornbierer, D; Palner, M; Quednow, BB; Martin-Soelch, C. Molecular and functional imaging studies of psychedelic drug action in animals and humans Molecules, 1 Jan 2021, 26 (9), 2451. 3.5 MB. https://doi.org/10.3390/molecules26092451 #30
Halberstadt, AL. Recent advances in the neuropsychopharmacology of serotonergic hallucinogens Behav. Brain Res., 15 Jan 2015, 277, 99–120. 4.1 MB. https://doi.org/10.1016/j.bbr.2014.07.016 #Lysergic acid (2S,4S)-2,4-dimeth
Tanaka, R; Kawamura, M; Mizutani, S; Kikura-Hanajiri, R. Identification of LSD analogs, 1cP-AL-LAD, 1cP-MIPLA, 1V-LSD and LSZ in sheet products Forensic Toxicol., 21 Feb 2023. 993 kB. https://doi.org/10.1007/s11419-023-00661-1 #4 LC,MS,NMR,UV
Duan, W; Cao, D; Wang, S; Cheng, J. Serotonin 2A receptor (5-HT2AR) agonists: Psychedelics and non-hallucinogenic analogues as emerging antidepressants Chem. Rev., 10 Jan 2024, 124 (1), 124–163. 12.6 MB. https://doi.org/10.1021/acs.chemrev.3c00375 #70